Donor lymphocyte infusion in Acute Myeloid Leukemia

Optimization of Donor Lymphocyte Infusion for AML Relapse After Allo-HCT in the Era of New Drugs and Cell Engineering

(2022) Yishan Ye et al.   Frontiers in Oncology

Venetoclax does not impair activated T-cell proliferation

(2021) Lama Siblany et al.   BONE MARROW TRANSPLANTATION

Pre-emptive use of Sorafenib combined with DLI post HSCT in AML FLT3+: a single center experience

(2021) Antonella Bruzzese et al.   BONE MARROW TRANSPLANTATION

Donor lymphocyte infusions after first allogeneic hematopoietic stem-cell transplantation in adults with acute myeloid leukemia: a single-center landmark analysis

(2021) Andrés R. Rettig et al.   ANNALS OF HEMATOLOGY

Targeted and cytotoxic therapies as maintenance treatment for non-transplant eligible patients with acute myeloid leukemia

(2021) Shyam A. Patel et al.   BLOOD REVIEWS

Treatment of AML Relapse After Allo-HCT

(2021) Jonathan A. Webster et al.   Frontiers in Oncology

Prediction of Response and Survival Following Treatment with Azacitidine for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes after Allogeneic Hematopoietic Stem Cell Transplantation

(2020) Christina Rautenberg et al.   Cancers

Prophylactic modified donor lymphocyte infusion after low-dose ATG-F-based haploidentical HSCT with myeloablative conditioning in high-risk acute leukemia: a matched-pair analysis

(2020) Luxin Yang et al.   BONE MARROW TRANSPLANTATION

Evaluation of Trends and Prognosis Over Time in Patients with AML Relapsing After Allogeneic Hematopoeitic Cell Transplant Reveals Improved Survival for Young Patients in Recent Years

(2020) Ali Bazarbachi et al.   CLINICAL CANCER RESEARCH

Treatment of myeloid malignancies relapsing after allogeneic hematopoietic stem cell transplantation with venetoclax and hypomethylating agents—a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group

(2020) Esther Schuler et al.   ANNALS OF HEMATOLOGY

Bone marrow central memory and memory stem T-cell exhaustion in AML patients relapsing after HSCT

(2019) Maddalena Noviello et al.   Nature Communications

Sorafenib Therapy Is Associated with Improved Outcomes for FMS-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Stem Cell Transplantation

(2019) Li Xuan et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Full donor chimerism without graft-versus-host disease: the key factor for maximum benefit of pre-emptive donor lymphocyte infusions (pDLI)

(2019) Jesus Feliu et al.   BONE MARROW TRANSPLANTATION

Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the acute leukemia working party of the EBMT

(2019) Bhagirathbhai Dholaria et al.   HAEMATOLOGICA

Donor selection for a second allogeneic stem cell transplantation in AML patients relapsing after a first transplant: a study of the Acute Leukemia Working Party of EBMT

(2019) Avichai Shimoni et al.   Blood Cancer Journal

Measurable residual disease, conditioning regimen intensity and age predict outcome of allogeneic hematopoietic cell transplantation for acute myeloid leukemia in first remission: a registry analysis of 2292 patients by the Acute Leukemia Working Party Eu

(2018) Maria H Gilleece et al.   AMERICAN JOURNAL OF HEMATOLOGY

Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia

(2018) Mithun Vinod Shah et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Epidemiology and biology of relapse after stem cell transplantation

(2018) Mary Horowitz et al.   BONE MARROW TRANSPLANTATION

Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes

(2018) Naval Daver et al.   LEUKEMIA

Sorafenib promotes graft-versus-leukemia activity in mice and humans through IL-15 production in FLT3-ITD-mutant leukemia cells

(2018) Nimitha R Mathew et al.   NATURE MEDICINE

Association of Second Allogeneic Hematopoietic Cell Transplant vs Donor Lymphocyte Infusion With Overall Survival in Patients With Acute Myeloid Leukemia Relapse

(2018) Mohamed A. Kharfan-Dabaja et al.   JAMA Oncology

Chemotherapy plus DLI for relapse after haploidentical HSCT: the biological characteristics of relapse influences clinical outcomes of acute leukemia patients

(2018) Wei Sun et al.   BONE MARROW TRANSPLANTATION

Immune Escape of Relapsed AML Cells after Allogeneic Transplantation

(2018) Matthew J. Christopher et al.   NEW ENGLAND JOURNAL OF MEDICINE

KIR3DL1/HLA-B Subtypes Govern Acute Myelogenous Leukemia Relapse After Hematopoietic Cell Transplantation

(2017) Jeanette E. Boudreau et al.   JOURNAL OF CLINICAL ONCOLOGY

Chemotherapy versus Hypomethylating Agents for the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome after Allogeneic Stem Cell Transplant

(2016) Ibraheem H. Motabi et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Phase II Study of Haploidentical Natural Killer Cell Infusion for Treatment of Relapsed or Persistent Myeloid Malignancies Following Allogeneic Hematopoietic Cell Transplantation

(2016) Brian C. Shaffer et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Improved Outcome of Refractory/Relapsed Acute Myeloid Leukemia after Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation with Myeloablative Conditioning and Early Prophylactic Granulocyte Colony-Stimulating Factor–Mobilized Donor Lymphocyte Infusions

(2016) Sarita Rani Jaiswal et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Relapse of AML after hematopoietic stem cell transplantation: methods of monitoring and preventive strategies. A review from the ALWP of the EBMT

(2016) P Tsirigotis et al.   BONE MARROW TRANSPLANTATION

Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia

(2016) C. Craddock et al.   HAEMATOLOGICA

Clinical activity of azacitidine in patients who relapse after allogeneic stem cell transplantation for acute myeloid leukemia

(2016) C. Craddock et al.   HAEMATOLOGICA

Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes

(2015) Hans C. Lee et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Survival of Patients with Acute Myeloid Leukemia Relapsing after Allogeneic Hematopoietic Cell Transplantation: A Center for International Blood and Marrow Transplant Research Study

(2015) Nelli Bejanyan et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Treatment strategies in patients with AML or high-risk myelodysplastic syndrome relapsed after Allo-SCT

(2015) T Sauer et al.   BONE MARROW TRANSPLANTATION

Donor Lymphocyte Infusion for the Treatment of Relapsed Acute Myeloid Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation: A Retrospective Analysis by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation

(2014) Akiyoshi Takami et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Donor Chimerism Early after Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation Predicts Relapse and Survival

(2014) John Koreth et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

A multicentre UK study of GVHD following DLI: Rates of GVHD are high but mortality from GVHD is infrequent

(2014) J J Scarisbrick et al.   BONE MARROW TRANSPLANTATION

DLI after haploidentical BMT with post-transplant CY

(2014) A Ghiso et al.   BONE MARROW TRANSPLANTATION

5-Azacytidine treatment sensitizes tumor cells to T-cell mediated cytotoxicity and modulates NK cells in patients with myeloid malignancies

(2014) A O Gang et al.   Blood Cancer Journal

HLA-Haploidentical Donor Lymphocyte Infusions for Patients with Relapsed Hematologic Malignancies after Related HLA-Haploidentical Bone Marrow Transplantation

(2013) Amer M. Zeidan et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Reversal of in situ T-cell exhaustion during effective human antileukemia responses to donor lymphocyte infusion

(2013) P. Bachireddy et al.   BLOOD

High Alloreactivity of Low-Dose Prophylactic Donor Lymphocyte Infusion in Patients with Acute Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation with an Alemtuzumab-Containing Conditioning Regimen

(2012) Maria Liga et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Treatment, risk factors, and outcome of adults with relapsed AML after reduced intensity conditioning for allogeneic stem cell transplantation

(2011) C. Schmid et al.   BLOOD

Escalated lymphodepletion followed by donor lymphocyte infusion can induce a graft-versus-host response without overwhelming toxicity

(2011) T Guillaume et al.   BONE MARROW TRANSPLANTATION

Superior Graft-versus-Leukemia Effect Associated with Transplantation of Haploidentical Compared with HLA-Identical Sibling Donor Grafts for High-Risk Acute Leukemia: An Historic Comparison

(2010) Yu Wang et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia

(2010) O. Goodyear et al.   BLOOD

Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited

(2010) Abhinav Deol et al.   CANCER TREATMENT REVIEWS

Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in First Complete Remission

(2009) John Koreth et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Human natural killer cells

(2008) M. A. Caligiuri   BLOOD